REFERENCES
- Price RW, Spudich S. Antiretroviral therapy and cen-tral nervous system HIV type 1 infection. J Infect Dis. 2008;197:S294–306.
- Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch NeuroL 2008;65(1):65–70.
- Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2)11–17.
- Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retrovirus. 2008;24(10):1301–1307.
- Mehling M, Drechsler H, Kuhle J, et al. Adaptation of anti-retroviral therapy in human immunodeficiency virus infec-tion with central nervous system involvement. J Neurovirol. 2008;14:78–84.
- Canestri A, Lescure X, Jaureguiberry S, et al. HIV-related meningoencephalitis in patients with optimally suppressed plasma HIV RNA receiving stable ART. In: Program and Abstracts of the16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 484a.